After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial
In the ASCENT-03 trial, Gilead's Trodelvy bested chemotherapy at extending the time before disease worsening or death in certain patients with previously untreated metastatic triple-negative breast cancer. The results help pad the case for Trodelvy in first-line breast cancer following positive results for a Trodelvy-Keytruda cocktail in a similar indication last month.
In the ASCENT-03 trial, Gilead's Trodelvy bested chemotherapy at extending the time before disease worsening or death in certain patients with previously untreated metastatic triple-negative breast cancer. The results help pad the case for Trodelvy in first-line breast cancer following positive results for a Trodelvy-Keytruda cocktail in a similar indication last month.
